GHRP-2: Effects, Side Effects, and Dosing Protocols

GHRP-2 (pralmorelin) is a synthetic peptide that acts as an agonist of ghrelin, the gut-derived hormone involved in growth hormone release and appetite regulation. Its primary effect is a potent, dose-dependent surge in growth hormone (GH) secretion from the pituitary gland, but it also raises cortisol, ACTH, and prolactin to a lesser degree and meaningfully increases hunger. Most of the human data comes from its clinical use as a diagnostic tool for GH deficiency and from small therapeutic trials in children with growth failure and adults with severe wasting conditions. The picture that emerges is of a peptide with reliable GH-releasing power, a handful of predictable side effects, and several open questions about long-term use.

How GHRP-2 Triggers Growth Hormone Release

GHRP-2 binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the body’s own ghrelin. Once bound, it sets off a signaling cascade inside pituitary somatotroph cells that results in a burst of GH. Research in pituitary cell cultures has shown that this process depends on calcium flowing into the cell through voltage-dependent calcium channels and involves both the protein kinase C and cyclic AMP (cAMP) pathways.¹ Interestingly, GHRP-2 raised intracellular cAMP levels in sheep somatotrophs in a way that closely resembled the natural GH-releasing hormone (GHRH), a property its older cousin GHRP-6 did not share.²

A key clinical feature is that GHRP-2 and GHRH amplify each other’s effects. When both are administered together, the resulting GH release is synergistic, meaning it exceeds what you would expect from simply adding the two individual responses together.³ This synergy has made combinations of GHRP-2 with GHRH or L-arginine a tool in clinical testing. In young men, the combination of L-arginine with GHRP-2 produced GH pulses roughly two to nearly three times larger than L-arginine combined with GHRH.⁴ The practical takeaway is that GHRP-2 works through a pathway that partly overlaps with, but is distinct from, the body’s own GHRH system, which is why combining the two produces an outsized response.

Effects on Growth Hormone and IGF-1

The most reliable effect of GHRP-2 is a sharp, short-lived spike in circulating GH. In animal models, intravenous injection produced dose-dependent GH peaks that returned to baseline within about two hours.⁵ In human adolescents tested for GH deficiency, those with intact pituitary function showed median GH peaks around 89 to 90 ng/mL after GHRP-2 administration, while those with organic GH deficiency (structural pituitary damage) peaked at only about 3.4 ng/mL, illustrating both the peptide’s potency and its dependence on having functional somatotroph cells.⁶

Whether those GH spikes translate into sustained increases in IGF-1, the downstream hormone that mediates most of GH’s tissue-building effects, is more complicated. In steers on a high-protein diet, GHRP-2 treatment did raise plasma IGF-1 levels, but the same treatment in steers on a low-protein diet had no effect, suggesting that nutritional status gates the IGF-1 response.⁷ Human data is more sobering. A study of men receiving low-dose GHRP-2 therapy found no significant change in serum IGF-1 levels across the whole group, with only a trend toward improvement in those who started with IGF-1 below 150 ng/mL. Body weight and body fat percentage also did not change.⁸ This gap between a reliable GH spike and a measurable downstream IGF-1 increase is one of the most important things to understand about GHRP-2: producing a pulse of GH is not the same as replicating the full metabolic profile of continuous GH therapy.

There is at least one dramatic exception. In a severely emaciated patient with anorexia nervosa, a year of intranasal GHRP-2 treatment gradually increased body weight, muscle mass, fat mass, and IGF-1 levels, along with improvements in muscle strength and daily activity.⁹ This suggests that in states of extreme deficiency or wasting, the peptide’s effects on GH and appetite may converge to produce meaningful gains, even when they fall short in healthier individuals.

Appetite Stimulation

Because GHRP-2 activates the same receptor as ghrelin, it shares ghrelin’s hunger-promoting effect. In healthy men infused with GHRP-2, food intake increased by about 36% compared to saline, and every single participant ate more.¹⁰ The effect is dose-dependent: a separate trial found that a low dose increased food intake by about 10%, while a higher dose pushed it up by roughly a third. Importantly, obese and lean subjects responded similarly, meaning obesity does not blunt this appetite drive.¹¹

For someone using GHRP-2 hoping to stay lean, this is a real concern. The hunger is not subtle, and it does not seem to habituate easily with continued use. For a wasting patient or someone struggling to eat enough, the same property becomes a potential benefit. Context determines whether appetite stimulation is a side effect or the whole point.

Other Hormonal Effects

GHRP-2 is not perfectly selective for GH. In human studies, it also produced mild but measurable increases in prolactin, ACTH, and cortisol.¹² The cortisol and ACTH rises have been described as comparable in magnitude to those produced by human corticotropin-releasing hormone, meaning they are real but not extreme. The prolactin bump is smaller than what you see from TRH, the hormone that physiologically stimulates prolactin release. Research in mouse pituitary cells confirmed that GHRP-2 directly stimulates both the release and the production of ACTH, not just an indirect effect through the hypothalamus.¹³

For someone taking a single diagnostic dose, these secondary hormonal shifts are clinically insignificant. The question that has not been adequately studied is what happens when GHRP-2 is used repeatedly over weeks or months. Chronic low-grade cortisol elevation, even if each individual spike is modest, could theoretically affect sleep quality, immune function, and metabolic health. The existing long-term trials in children (discussed below) did not flag cortisol-related problems, but those trials used low doses and monitored for only specific outcomes.

Clinical Uses

The most established clinical application of GHRP-2 is as a provocative agent for diagnosing GH deficiency. In Japan, it is approved under the name pralmorelin for this purpose. The logic is straightforward: give GHRP-2 intravenously, measure the resulting GH peak, and compare it to a cutoff. A peak below 15 µg/L is used to identify patients with GH deficiency, while healthy individuals generally exceed this threshold regardless of sex, weight, or age.¹⁴ Urine-based detection methods have been developed to identify the peptide and its metabolites, which are detectable for up to about 47 hours after nasal administration.¹⁵

Therapeutic trials have been small but encouraging. Six prepubertal children with GH deficiency received subcutaneous GHRP-2 at escalating doses (0.3, 1.0, and 3.0 µg/kg/day) over eight months. Growth velocity improved during treatment compared to both pretreatment and post-treatment periods, and no side effects or toxicities were observed.¹⁶ A separate study using intranasal delivery in children with short stature found that height velocity rose from about 3.7 cm/year at baseline to 6.1 cm/year at six months, sustained at 6.0 cm/year out to 18–24 months. The treatment was well tolerated.¹⁷ The growth increases were described as modest but significant, and the researchers in the subcutaneous trial concluded that GHRP-2 could be useful for treating GH-deficient children.¹⁸

Despite these results, GHRP-2 has not become a mainstream therapeutic option for GH deficiency. Recombinant human GH remains the standard treatment because it directly supplies the missing hormone rather than relying on the pituitary to produce it. GHRP-2’s niche remains diagnostic testing and investigational use in conditions like severe cachexia, where its combined effects on GH release and appetite are uniquely suited to the problem.

Side Effects

The side-effect profile of GHRP-2 is generally mild in the short-term studies available. The most commonly reported effects include increased appetite (discussed above), flushing or warmth at the injection site or face, transient drowsiness with evening dosing, mild water retention, and increased gut motility. Less commonly, people experience numbness or tingling in the hands and feet, joint stiffness, and lightheadedness shortly after injection.

The hormonal side effects deserve specific attention. As noted earlier, GHRP-2 raises cortisol and ACTH with each dose. It also mildly elevates prolactin.¹² In the eight-month pediatric trial, no clinical toxicities were flagged.¹⁶ In a rabbit model of prolonged critical illness, GHRP-2 combined with TRH did not worsen mortality, organ function, or hyperglycemia compared to other treatment arms, although insulin was adjusted to keep blood glucose below 180 mg/dL.¹⁹

The honest assessment is that the long-term safety data in adults using GHRP-2 at self-directed doses simply does not exist in the published literature. The clinical trials are short, use low doses, and involve small numbers of patients. Anyone extrapolating from these to months of daily subcutaneous injections at higher doses is operating in uncharted territory.

Dosing, Delivery, and Pharmacokinetics

In animal pharmacokinetic studies, GHRP-2 (referred to by its early research designation SK&F 110679) showed very high bioavailability when injected subcutaneously, in the range of 89–103%. After intravenous dosing, the initial half-life in plasma was extremely short, just two to four minutes, reflecting rapid distribution out of the bloodstream. An apparent terminal half-life of about one hour after subcutaneous injection likely reflects slow absorption from the injection site rather than the peptide lingering in circulation.²⁰

Nasal delivery is a viable alternative. Pharmacokinetic evaluation of several growth hormone secretagogues found that GHRP-2 had nasal bioavailability of roughly 50%, which was among the highest in the class tested.²¹ The intranasal children’s trials used this route successfully for up to two years, suggesting it is practical even for extended treatment.

The clinical trials that measured growth effects in children used subcutaneous doses ranging from 0.3 to 3.0 µg/kg/day.¹⁶ Doses used in adult diagnostic testing and appetite research have typically been in the range of 1 µg/kg intravenously. Most of the dosing protocols that circulate in non-clinical settings (commonly 100–300 µg per injection, two to three times daily) are not derived from published trials and should be understood as anecdotal.

Desensitization With Repeated Dosing

One practical concern for anyone considering frequent GHRP-2 administration is desensitization. In calves, continuous exposure to GHRP-2 blunted the GH response to a subsequent GHRP-2 bolus, and this attenuation persisted for up to four hours after the continuous infusion ended. However, the GH response to GHRH was not attenuated, meaning the desensitization was specific to the GHRP-2 receptor pathway, not a general pituitary fatigue.²² This finding suggests that spacing doses several hours apart is important to maintain the GH response, and that combining GHRP-2 with GHRH may help preserve efficacy even when some receptor desensitization is occurring.

The four-hour window observed in calves is often cited as the rationale behind twice- or three-times-daily dosing schedules. Whether the same timeline applies in humans has not been formally established, but the biology of receptor desensitization is broadly similar across mammals, so the principle is reasonable even if the exact interval could differ.

Who Responds Differently

Not everyone gets the same GH response from GHRP-2. Sex appears to be a major modifier. During protracted critical illness, women showed supranormal GH responses to GHRP-2 that were dramatically higher than men’s, averaging about 93 µg/L in women compared to 28 µg/L in men.²³ This sex difference appears to reflect hormonal modulation of the GH axis rather than anything specific to the peptide, but it means that women and men may require different doses to achieve comparable GH output.

Body composition also matters, though perhaps not in the way you’d expect. While obesity blunts the GH response to many stimuli, the appetite-stimulating effect of GHRP-2 is not diminished in obese subjects.¹¹ Nutritional status further complicates the picture, as the IGF-1 response appears to depend on adequate protein intake.⁷ And testosterone levels do not seem to be a major factor: experimentally lowering testosterone in young men did not significantly impair the GH response to GHRP-2.⁴

Anti-Inflammatory and Tissue-Protective Properties

Beyond its endocrine effects, GHRP-2 has shown anti-inflammatory activity in animal models that appears to be independent of its ability to release GH. In rats with adjuvant-induced arthritis, GHRP-2 treatment reduced the clinical arthritis score, decreased paw swelling, and lowered circulating levels of the inflammatory marker IL-6. In cell culture, both GHRP-2 and ghrelin prevented endotoxin-stimulated IL-6 release from macrophages, suggesting a direct anti-inflammatory mechanism acting through ghrelin receptors on immune cells themselves.²⁴

A broader review of growth hormone-releasing peptides described antioxidant properties for GHRP-2 as well, including reduced peroxide generation in cultured aortic smooth muscle cells and downregulation of inflammatory gene expression in atherosclerosis-prone mice.²⁵ These findings are preclinical and have not been tested in human inflammatory disease, but they point to biological activity beyond what you would expect from a simple GH secretagogue. Whether this translates to any clinical benefit in people remains an open question.

GHRP-2 and Anti-Doping

GHRP-2 and related peptides appear on the World Anti-Doping Agency’s Prohibited List as growth hormone secretagogues. Detection methods have become increasingly sensitive. After nasal administration of GHRP-2, the parent peptide and two metabolites (GHRP-2 free acid and a fragment) were detectable in urine for up to 47 hours using high-resolution mass spectrometry techniques.²⁶ These metabolites have been incorporated into routine anti-doping screening procedures, meaning that even a single dose taken within two days of a test is likely to be caught. For competitive athletes, the detection window and the prohibited status make GHRP-2 use a clear doping violation with a high probability of getting flagged.

How GHRP-2 Compares to GHRP-6

GHRP-6 is the older and more widely known peptide in the GHRP family, and comparisons between the two come up frequently. Despite significant structural differences, GHRP-2 and GHRP-6 appear to stimulate GH release through the same receptor and the same downstream mechanism in pituitary cells.²⁷ However, there are meaningful pharmacological differences. GHRP-2 raises intracellular cAMP in somatotrophs in a manner similar to GHRH, while GHRP-6 does not.² This additional signaling pathway may partly explain why GHRP-2 is generally regarded as the more potent GH releaser of the two.

On the appetite side, GHRP-6 is often reported anecdotally to cause stronger hunger than GHRP-2, though head-to-head human comparisons in controlled settings are sparse. Nasal bioavailability also favors GHRP-2, which achieved roughly 50% absorption through the nasal mucosa compared to somewhat lower absorption for GHRP-6.²¹ For anyone choosing between the two, GHRP-2 offers stronger GH release per dose and more delivery flexibility, while GHRP-6 may be preferred specifically when appetite stimulation is the primary goal.